.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,491,935

« Back to Dashboard

Details for Patent: 8,491,935

Title:Modified release formulations containing drug-ion exchange resin complexes
Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Inventor(s): Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee: Tris Pharma, Inc. (Monmouth Junction, NJ)
Filing Date:Nov 01, 2012
Application Number:13/666,424
Claims:1. An orally ingestible aqueous pharmaceutical suspension composition comprising: (A) barrier coated particulates which provide about a twelve hour release profile which comprise (i) a particulate matrix comprising a particulate hydrocodone-cation exchange resin complex and a water insoluble polymer or copolymer or a hydrophilic polymer, said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or hydrophilic polymer) matrix capable of passing through a number 40 mesh screen, said particulate hydrocodone-cation exchange resin complex comprising hydrocodone bound to a pharmaceutically acceptable water insoluble cation exchange resin, wherein said water insoluble polymer or copolymer, or hydrophilic polymer, is present in said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or hydrophilic polymer) matrix in an amount of about 3% to about 30% by weight, based on the weight of said particulate hydrocodone-cation exchange resin complex, and (ii) a cured high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating over said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or said hydrophilic polymer) matrix defined in (i), said cured barrier coating applied as an aqueous dispersion, said cured barrier coating comprising: (a) about 70% w/w to about 90% w/w polyvinylacetate polymer, (b) a stabilizer, and (c) about 2.5 to about 20% w/w of plasticizer effective to enhance the tensile strength of said cured barrier coating, whereby said cured coating provides about a twelve hour release profile to the hydrocodone in said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or hydrophilic polymer) matrix), wherein the weight percentage is based on the weight of the cured barrier coating layer; (B) an uncoated particulate drug-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, wherein said uncoated drug-cation exchange resin complex is a dl-chlorpheniramine bound to a pharmaceutically acceptable water insoluble cation exchange resin complex or a dexchlorpheniramine bound to a pharmaceutically acceptable water insoluble cation exchange resin; and (C) a pharmaceutically acceptable aqueous suspension base, wherein said coated particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or or hydrophilic polymer) matrix defined in (ii) and said uncoated particulate drug-ion exchange resin complex defined in (B) are suspended in said base.

2. The composition according to claim 1 wherein said cured high tensile strength, water permeable, water insoluble non-ionic polymeric diffusion barrier coating has an elongation factor of between about 125% and about 400%.

3. The composition according to claim 1, wherein said barrier coating is applied as an aqueous dispersion comprising about 30% solids comprising polyvinylacetate, polyvinylpyrrolidone and an effective amount of a surfactant, said polyvinylacetate and polyvinylpyrrolidone being in a dry weight ratio about 10:1.

4. The composition according to claim 1, wherein said plasticizer is present in an amount of about 5% to about 10% w/w of said cured coating.

5. The composition according to claim 4 wherein said plasticizer comprises triacetin.

6. The composition according to claim 1 wherein said barrier coating further comprises a surfactant comprising sodium lauryl sulfate.

7. The composition according to claim 1, wherein said cured, high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating is about 35% to about 50% by weight of said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or hydrophilic polymer) matrix defined in (i).

8. The composition according to claim 1, wherein said water insoluble polymer or copolymer or the hydrophilic polymer matrix is present in an amount of about 5 to about 20% by weight, based on the weight of said particulate hydrocodone-cation exchange resin complex defined in (i).

9. The composition according to claim 1, wherein said cation exchange resin used to form the complex of (i) and said cation exchange resin used to form the complex of (B) are selected from different pharmaceutically acceptable cation resins.

10. The composition according to claim 1, wherein said cation exchange resin used to form the complex of (i) and said cation exchange resin used to form the complex of (B) are the same pharmaceutically acceptable cation resin.

11. The composition of claim 1, wherein said cation exchange resin used to form the complex of (B) is a copolymer comprising methacrylic acid and a divinylbenzene.

12. The composition according to claim 1, wherein said cation exchange resin used to form the complex of (i) and (B) is a copolymer comprising styrene and a divinylbenzene.

13. The composition according to claim 1, wherein said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer or copolymer or hydrophilic polymer) matrix includes a hydrophilic polymer.

14. The composition according to claim 13, wherein said hydrophilic polymer comprises a polyvinylpyrrolidone.

15. The composition according to claim 1, wherein said particulate matrix comprises said particulate hydrocodone-cation exchange resin complex and a water insoluble polymer or copolymer.

16. The composition according to claim 15, wherein said water insoluble polymer or copolymer in said particulate matrix is polvvinylacetate and said particulate matrix further comprises a stabilizer comprising polyvinylpyrrolidone and an effective amount of a surfactant.

17. The composition according to claim 16, wherein said particulate matrix is prepared by a process comprising mixing said particulate hydrocodone-cation exchange resin complex with an aqueous dispersion comprising the water insoluble polymer polyvinylacetate together with polyvinylpyrrolidone and a sodium lauryl sulfate surfactant to form a mass, drying said mass and milling through a 40 mesh screen, and wherein said polyvinylacetate is present in an amount of about 27% w/w of said aqueous dispersion, said polyvinylpyrrolidone is present in an amount of about 2.7% w/w of said aqueous dispersion, and said sodium lauryl sulfate is present in an amount of about 0.3% w/w of said aqueous dispersion which comprises 30% solids.

18. The composition according to claim 1, wherein said water insoluble polymer or copolymer in said particulate matrix comprises an acrylate polymer or copolymer.

19. The composition according to claim 18, wherein said water insoluble polymer or copolymer in said particulate matrix comprises a copolymer comprising ethyl acrylate and methyl methacrylate.

20. An orally ingestible aqueous pharmaceutical suspension composition, comprising (A) barrier coated particulates which provides about a twelve hour release profile: (i) a particulate matrix comprising a particulate hydrocodone-cation exchange resin complex and a water insoluble polymer, said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer) matrix capable passing through a number 40 mesh screen, said particulate hydrocodone-cation exchange resin complex comprising hydrocodone bound to a pharmaceutically acceptable water insoluble cation exchange resin, wherein said water insoluble polymer is present in an amount of about 3% to about 30% by weight, based on the weight of said particulate hydrocodone-cation exchange resin complex--(water-insoluble polymer) matrix defined in (i), and wherein said water insoluble cation exchange resin is a copolymer comprising styrene and a divinylbenzene; (ii) a cured high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating over said hydrocodone-cation exchange resin complex--(water insoluble polymer) matrix defined in (i), said cured barrier coating applied as an aqueous dispersion, said cured barrier coating comprising (a) about 75% w/w to about 90% w/w polyvinylacetate polymer, (b) a stabilizer, and (c) about 2.5 to about 20% w/w of plasticizer effective to enhance the tensile strength of said cured barrier coating, whereby said cured coating provides a modified release profile to the drug in said drug- ion exchange resin complex in said matrix; and (B) an uncoated particulate dl-chlorpheniramine-cation exchange resin complex of a size capable of passing through a number 40 mesh screen, said complex comprising dl-chlorpheniramine bound to a pharmaceutically acceptable water insoluble cation exchange resin which comprises a copolymer of styrene and a divinylbenzene; and (C) a pharmaceutically acceptable aqueous suspension base, wherein said coated particulate hydrocodone-cation exchange resin complex (water-insoluble polymer) matrix defined in (ii) and said uncoated particulate dl-chlorpheniramine-cation exchange resin complex defined in (B) are suspended in said base.

21. The composition according to claim 20, wherein said water insoluble polymer in said particulate matrix comprises polyvinylacetate and said particulate matrix further comprises a stabilizer comprising polyvinylpyrrolidone and a surfactant.

22. The composition according to claim 21, wherein said particulate matrix is prepared by a process comprising mixing said particulate hydrocodone-cation exchange resin complex with an aqueous dispersion comprising polyvinylacetate, polyvinylpyrrolidone and a sodium lauryl sulfate surfactant to form a mass, drying said mass and milling through a 40 mesh screen.

23. The composition according to claim 20, wherein said cured, high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating is about 35% to about 50% by weight of said particulate hydrocodone-cation exchange resin complex--(water insoluble polymer) matrix defined in (i).

24. The composition according to claim 23, wherein said cured, high tensile strength, water permeable, water insoluble, non ionic polymeric diffusion barrier coating comprises about 50% by weight of the matrix defined in (i).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc